Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ResMed, a developer and manufacturer of medical equipment for treating respiratory disorders, has launched the Serve-HF study to investigate the use of its AutoSet CS2 device in the treatment of sleep-disordered breathing that affects patients with chronic heart failure.
Subscribe to our email newsletter
The international Serve-HF study will focus specifically on the impact of treatment of central sleep apnea (CSA) in patients with heart failure. According to the company, up to 76% of patients with heart failure also suffer from sleep-disordered breathing, in which normal breathing during sleep is interrupted. Around two-thirds of those patients with clinically significant sleep-disordered breathing have CSA.
During the four-year Serve-HF study, physicians will examine the long-term benefits and the cost-effectiveness of the breathing support provided by the AutoSet CS2 for the treatment of heart failure patients.
The AutoSet CS2 is an intuitive ventilator that monitors breathing constantly throughout the night, said ResMed. In a process known as adaptive servo-ventilation, it takes into consideration breathing rate and the amount of air inhaled and exhaled. When the device detects any changes in either of these factors, it helps maintain normal breathing, the company added.
It is anticipated that the study, funded by ResMed, will help physicians to better understand how heart failure progression can be reduced during treatment with adaptive servo-ventilation. It will also provide researchers with valuable information on the effect of heart failure on key factors such as hospitalization, quality of life, and the ability to exercise, according to ResMed.
The researchers plan to recruit 1,260 heart failure patients at 80 clinics across Germany, France, the UK, Norway, Sweden, Denmark and the US.